Results 101 to 110 of about 414,704 (315)

Blood-brain barrier P-glycoprotein function in Alzheimer's disease [PDF]

, 2011
A major pathological hallmark of Alzheimer's disease is accumulation of amyloid-beta in senile plaques in the brain. Evidence is accumulating that decreased clearance of amyloid-beta from the brain may lead to these elevated amyloid-beta levels.
Windhorst, Albert D., Assema, D.M.E. van, Flier, W.M. van der, Hoetjes, Nikie J., Tolboom, Nelleke, Emile F. I. Comans, Mark Lubberink, Lubberink, J.M., Philip Scheltens, Windhorst, A.D., Hoetjes, N.J., Scheltens, P., Bauer, Martin, van der Flier, W.M., Comans, Emile F. I., Schuit, R.C., Lammertsma, Adriaan A., Robert C. Schuit, Mueller, Markus, Daniëlle M. E. van Assema, Albert D. Windhorst, Lubberink, Mark,, Berckel, B.N.M. van, Schuit, Robert C., Muller, M., Comans, E.F.I., van Assema, Danielle M. E., van Berckel, B.N.M., Martin Bauer, Markus Müller, Bart N. M. van Berckel, van Berckel, Bart N. M., Bauer, M.C.R., Lammertsma, A.A., van der Flier, Wiesje M., Wiesje M. van der Flier, van Assema, D.M.E., Nikie J. Hoetjes, Langer, Oliver, Oliver Langer, Tolboom, N., Adriaan A. Lammertsma, Langer, O., Scheltens, Philip, Nelleke Tolboom   +44 more
core   +1 more source

Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma

Communications Materials
The blood-brain barrier, essential for protecting the central nervous system, also restricts drug delivery to this region. Thus, delivering drugs across the blood-brain barrier is an active research area in immunology, oncology, and neurology; moreover ...
Nassir Mokarram, Ayden Case, Nadia N. Hossainy, Johnathan G. Lyon, Tobey J. MacDonald, Ravi Bellamkonda   +5 more
doaj   +1 more source

Beyond wrecking a wall: revisiting the concept of blood–brain barrier breakdown in ischemic stroke

Neural Regeneration Research
The blood–brain barrier constitutes a dynamic and interactive boundary separating the central nervous system and the peripheral circulation. It tightly modulates the ion transport and nutrient influx, while restricting the entry of harmful factors, and ...
Julia Castillo-González, Elena González-Rey   +1 more
doaj   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis [PDF]

, 2012
Background Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza)
Hunter, Kerry, Holscher, Christian, Hunter Kerry, Hölscher Christian, Kerry Hunter, Christian Holscher   +5 more
core   +1 more source

Function of Connexins in the Interaction between Glial and Vascular Cells in the Central Nervous System and Related Neurological Diseases

Neural Plasticity, 2018
Neuronal signaling together with synapse activity in the central nervous system requires a precisely regulated microenvironment. Recently, the blood-brain barrier is considered as a “neuro-glia-vascular unit,” a structural and functional compound ...
Yinan Zhao, Yanguo Xin, Zhiyi He, Wenyu Hu   +3 more
doaj   +1 more source

Normal‐Appearing White Matter Injury Mediates Chronic Deep Venous Hypoxia and Disease Progression in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore how cerebral hypoxia and Normal‐Appearing White Matter (NAWM) integrity affect MS lesion burden and clinical course. Methods Seventy‐nine MS patients, including 13 clinically isolated syndrome (CIS) patients and 66 relapsing–remitting multiple sclerosis (RRMS) patients, and 44 healthy controls (HCs) were recruited from ...
Xinli Wang, Huiying Wang, Zhizheng Zhuo, Ai Guo, Ke Lv, Decai Tian, Chao Chai, Yunyun Duan, Shuang Xia   +8 more
wiley   +1 more source

Tissue plasminogen activator enhances the hypoxia/reoxygenation-induced impairment of the blood-brain barrier in a primary culture of rat brain endothelial cells. [PDF]

, 2008
Hemorrhagic transformation is a major complication associated with tissue plasminogen activator (tPA) therapy for ischemic stroke. We studied the effect of tPA on the blood-brain barrier (BBB) function with our in vitro monolayer model generated using ...
Nagata, Izumi, Tsutsumi, Keisuke, Suyama, Kazuhiko, Hayashi, Kentaro, Kawakubo, Junichi, Hiu, Takeshi, Kitagawa, Naoki, Niwa, Masami, Nakagawa, Sinsuke, Honda, Masaru   +9 more
core   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Quantitative PET imaging and modeling of molecular blood-brain barrier permeability

Nature Communications
Neuroimaging of blood-brain barrier permeability has been instrumental in identifying its broad involvement in neurological and systemic diseases. However, current methods evaluate the blood-brain barrier mainly as a structural barrier. Here we developed
Kevin J. Chung, Yasser G. Abdelhafez, Benjamin A. Spencer, Terry Jones, Quyen Tran, Lorenzo Nardo, Moon S. Chen, Souvik Sarkar, Valentina Medici, Victoria Lyo, Ramsey D. Badawi, Simon R. Cherry, Guobao Wang   +12 more
doaj   +1 more source